With Biovica offering significant upside potential over the next 6 to 18 months, Redeye raises our base case fair value to SEK 95 (46). DiviTum’s FDA approval will reduce risk and bring commercial clinical sales, while subsequent private use and public reimbursement should propel volumes and clinical support. In addition, the case is bolstered by potential expansion beyond the core market of advanced metastatic breast cancer (mBC).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Biovica - Premium potential

© Modular Finance, source Nordic Press Releases